Trial record 1 of 1 for:    03011931
Previous Study | Return to List | Next Study

Simvastatin Metabolism as a Test for CD Activity (IRB 15-007568]

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03011931
Recruitment Status : Recruiting
First Posted : January 6, 2017
Last Update Posted : March 21, 2018
Information provided by (Responsible Party):
Joseph A. Murray, M.D., Mayo Clinic

Brief Summary:
To study the correlation between simvastatin metabolism by the enterocyte and the histologic state of the intestine in treated celiac disease.

Condition or disease Intervention/treatment Phase
Celiac Disease Drug: Simvastatin Not Applicable

Detailed Description:
A cross sectional design incorporating subjects with active celiac disease and healed celiac disease (based on clinically-obtained biopsies); and healthy individuals.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Simvastatin Metabolism as a Test for Celiac Disease Activity
Study Start Date : March 2016
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : March 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Celiac Disease
Drug Information available for: Simvastatin

Arm Intervention/treatment
Experimental: Simvastatin
Simvastatin tablet, 20 mg, one time by mouth
Drug: Simvastatin
20 mg Simvastatin given, Blood draw, Urine collection, Celiac serology testing, DNA sampling, Dietary review
Other Name: Zocor

Primary Outcome Measures :
  1. Compare simvastatin metabolism with intestinal biopsies [ Time Frame: Within one month of visit ]

Secondary Outcome Measures :
  1. Villous height and crypt depth [ Time Frame: Within 1 month of visit ]
    As measured in intestinal biopsies

  2. Dietary interview [ Time Frame: At initial visit ]
    To determine whether the patient is strictly adherent, mostly adherent or non-adherent to a gluten-free diet

  3. Urinalysis [ Time Frame: Prior to administration of simvastatin and at the 3-hour mark ]
    Looking for traces of gluten peptides

  4. Serologic testing [ Time Frame: Prior to administration of simvastatin ]
    tTG IgA titer level determination

  5. DNA sampling [ Time Frame: Prior to administration of simvastatin ]
    Genetic testing associated with celiac disease (DQ2 and DQ8)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Gluten-free diet for at least 1 year
  2. Clinical endoscopy within the past month
  3. Biopsies must show no villous atrophy or villous blunting
  4. Villous height to crypt depth (VHCD) ratio measurement should be 2.5:1 or greater

Exclusion Criteria:

  1. 1st degree relative with Celiac Disease
  2. Positive tTG IgA, already on simvastatin or statin agent
  3. Unable to stop non-steroidal or anti-inflammatory drugs
  4. Prior history of GI surgery other than appendectomy or cholecystectomy
  5. Taking drugs know to inhibit or activate CYP3A4
  6. Unable to avoid food known to inhibit CYP3A4
  7. History of a reaction to statin drugs in the past
  8. Pregnant or nursing women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03011931

Contact: Chad Hinson 507-266-0237
Contact: Carol Van Dyke 207-266-7842

United States, Minnesota
Mayo Clinic in Rochester Recruiting
Rochester, Minnesota, United States, 55905
Contact: Carol Van Dyke    507-266-7842   
Contact: Chad Hinson    507-266-0237   
Sponsors and Collaborators
Mayo Clinic
Principal Investigator: Joseph A Murray, MD Mayo Clinic

Responsible Party: Joseph A. Murray, M.D., Professor of Medicine, Mayo Clinic Identifier: NCT03011931     History of Changes
Other Study ID Numbers: 15-007568
First Posted: January 6, 2017    Key Record Dates
Last Update Posted: March 21, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Celiac Disease
Malabsorption Syndromes
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Metabolic Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors